• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

作者信息

Gurnari Carmelo, Piciocchi Alfonso, Soddu Stefano, Bonanni Fabrizio, Scalzulli Emilia, Niscola Pasquale, Di Veroli Ambra, Piccioni Anna Lina, Piedimonte Monica, Maiorana Gianluca, Salutari Prassede, Cicconi Laura, Santopietro Michelina, Gumenyuk Svitlana, Sarlo Chiara, Fenu Susanna, Tafuri Agostino, Latagliata Roberto, Fianchi Luana, Criscuolo Marianna, Maciejewski Jaroslaw P, Maurillo Luca, Buccisano Francesco, Breccia Massimo, Voso Maria Teresa

机构信息

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Blood Cancer J. 2022 Sep 7;12(9):132. doi: 10.1038/s41408-022-00724-3.

DOI:10.1038/s41408-022-00724-3
PMID:36071048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9452671/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9637/9452671/5ae405aed575/41408_2022_724_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9637/9452671/5ae405aed575/41408_2022_724_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9637/9452671/5ae405aed575/41408_2022_724_Fig1_HTML.jpg

相似文献

1
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.伴有5号染色体长臂缺失的骨髓增生异常综合征：关于长期预后决定因素及来那度胺反应的真实研究。
Blood Cancer J. 2022 Sep 7;12(9):132. doi: 10.1038/s41408-022-00724-3.
2
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.来那度胺治疗孤立性del(5q)的原发性骨髓增生异常综合征：真实世界中的反应和生存决定因素
Am J Hematol. 2022 Oct;97(10):E377-E379. doi: 10.1002/ajh.26672. Epub 2022 Aug 12.
3
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.来那度胺治疗低危del(5q)骨髓增生异常综合征患者的短期和长期益处。
Ann Oncol. 2016 Jan;27(1):62-8. doi: 10.1093/annonc/mdv488. Epub 2015 Oct 26.
4
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.来那度胺在 del(5q) 骨髓增生异常综合征疗效中的多效作用机制。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.
5
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.伴 del(5q)骨髓增生异常综合征患者接受来那度胺治疗后的形态学分析：一项日本多机构研究。
Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15.
6
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.在出现输血依赖之前，对伴有del(5q)的低危和中危-1国际预后评分系统风险的骨髓增生异常综合征进行早期来那度胺治疗。
Cancer Med. 2015 Dec;4(12):1789-97. doi: 10.1002/cam4.523. Epub 2015 Sep 17.
7
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.来那度胺诱导 CD34(+) 细胞中 miR-145 表达与 del(5q) 骨髓增生异常综合征患者临床反应和反应持续时间的相关性。
Haematologica. 2013 Mar;98(3):409-13. doi: 10.3324/haematol.2012.066068. Epub 2012 Aug 28.
8
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).TP53 和 SF3B1 基因突变患者伴 5q- 骨髓增生异常综合征（MDS）的治疗结果和预后影响。
Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e467-e476. doi: 10.1016/j.clml.2022.01.002. Epub 2022 Jan 10.
9
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.对伴有 del(5q)骨髓增生异常综合征患者骨髓微环境进行深度测序，揭示了免疫原性选择的痕迹，以及作为来那度胺反应模式产生新的 T 细胞簇。
Haematologica. 2019 Jul;104(7):1355-1364. doi: 10.3324/haematol.2018.208223. Epub 2019 Jan 17.
10
Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.来那度胺治疗 5q- 与非 5q- 骨髓增生异常综合征。
Semin Hematol. 2012 Oct;49(4):312-22. doi: 10.1053/j.seminhematol.2012.07.001.

引用本文的文献

1
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).来那度胺对伴有5号染色体长臂缺失的骨髓增生异常综合征患者的疗效：来自希腊国家骨髓增生异常综合征与再生障碍性贫血综合征登记处（EAKMYS）的真实世界数据。
Cancers (Basel). 2025 Apr 22;17(9):1388. doi: 10.3390/cancers17091388.
2
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances.揭开骨髓增生异常综合征的面纱：探索致病机制与治疗进展
Cancers (Basel). 2025 Feb 3;17(3):508. doi: 10.3390/cancers17030508.
3
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.

本文引用的文献

1
Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.免疫抑制治疗后重型再生障碍性贫血患者克隆演变和髓系肿瘤的预测因素。
Leukemia. 2022 Sep;36(9):2328-2337. doi: 10.1038/s41375-022-01636-8. Epub 2022 Jul 27.
2
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series.病例报告：来那度胺在5号染色体长臂缺失（Del(5q)）中的个性化治疗方法：病例系列
Front Oncol. 2022 Mar 31;12:866470. doi: 10.3389/fonc.2022.866470. eCollection 2022.
3
Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.
低危骨髓增生异常综合征相关贫血的治疗。
Curr Treat Options Oncol. 2024 Jun;25(6):752-768. doi: 10.1007/s11864-024-01217-0. Epub 2024 May 30.
4
Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms.骨髓增生异常综合征的最新见解与治疗进展
Cancers (Basel). 2024 Apr 19;16(8):1563. doi: 10.3390/cancers16081563.
5
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?伴有del(5q)的骨髓增生异常综合征中治疗引发的突变——来那度胺相关还是疾病内在的克隆进化？
Blood Cancer J. 2024 Mar 18;14(1):49. doi: 10.1038/s41408-024-01027-5.
6
Association between Leukemic Evolution and Uncommon Chromosomal Alterations in Pediatric Myelodysplastic Syndrome.小儿骨髓增生异常综合征中白血病演变与罕见染色体改变之间的关联
Mediterr J Hematol Infect Dis. 2024 Jan 1;16(1):e2024003. doi: 10.4084/MJHID.2024.003. eCollection 2024.
7
Low ALT, a marker of sarcopenia and frailty, is associated with shortened survival amongst myelodysplastic syndrome patients: A retrospective study.低丙氨酸转氨酶（ALT），肌少症和衰弱的标志物，与骨髓增生异常综合征患者的生存期缩短相关：一项回顾性研究。
Medicine (Baltimore). 2023 Apr 25;102(17):e33659. doi: 10.1097/MD.0000000000033659.
8
Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.骨髓增生异常肿瘤（MDS）的分子驱动因素-分类和预后相关性。
Cells. 2023 Feb 15;12(4):627. doi: 10.3390/cells12040627.
9
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.我如何管理不符合移植条件的骨髓增生异常肿瘤患者。
Clin Hematol Int. 2023 Mar;5(1):8-20. doi: 10.1007/s44228-022-00024-4. Epub 2022 Dec 27.
10
Management of patients with lower-risk myelodysplastic syndromes.低危骨髓增生异常综合征患者的治疗管理。
Blood Cancer J. 2022 Dec 14;12(12):166. doi: 10.1038/s41408-022-00765-8.
低危骨髓增生异常综合征患者的促红细胞生成素水平及红系分化参数
Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10.
4
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.5q 缺失型骨髓增生异常综合征 10 年进展
Leukemia. 2018 Jul;32(7):1493-1499. doi: 10.1038/s41375-018-0029-9. Epub 2018 Jan 30.
5
Variable selection - A review and recommendations for the practicing statistician.变量选择——给执业统计学家的一篇综述与建议
Biom J. 2018 May;60(3):431-449. doi: 10.1002/bimj.201700067. Epub 2018 Jan 2.
6
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.低危和中危1型伴del(5q)的骨髓增生异常综合征患者的病情进展可由有限的一组突变预测。
Haematologica. 2017 Mar;102(3):498-508. doi: 10.3324/haematol.2016.152025. Epub 2016 Nov 24.
7
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).来那度胺治疗的伴有孤立性5号染色体长臂缺失（5q-）的骨髓增生异常综合征患者中TP53突变的患病率、克隆动力学及临床影响：德国骨髓增生异常综合征研究组（GMDS）一项前瞻性多中心研究的结果
Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2.
8
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.低危 del(5q) MDS 患者对红细胞反应的来那度胺治疗后延长生存期且 AML 进展风险降低。
Leukemia. 2014 May;28(5):1033-40. doi: 10.1038/leu.2013.305. Epub 2013 Oct 22.
9
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.对伴有 del(5q)的骨髓增生异常综合征使用来那度胺的反应：细胞遗传学和突变的影响。
Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25.
10
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.重新探讨 5q 髓系恶性肿瘤的解剖学、临床和基因组相关性。
J Clin Oncol. 2012 Apr 20;30(12):1343-9. doi: 10.1200/JCO.2011.36.1824. Epub 2012 Feb 27.